Investigation, Treatment and Monitoring of Late-Onset Hypogonadism in Males

Nieschlag, Eberhard; Swerdloff, Ronald S.; Hm, Behre; Gooren, L. J. G.; Kaufman, Jean; Jj, Legros; Lunenfeld, Bruno; Morley, John E.; Schulman, Claude; Wang, C.; Weidner, W.; Wu, F. C. W.

doi:10.1016/j.eururo.2005.04.027

Cited by 189 publications

(44 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Testosterone is an anabolic hormone that has been demonstrated to increase muscle mass and strength in older hypogonadal men when given at high doses [21][22][23][24][25][26][27][28][29]. A small number of studies suggest similar effects in women [30,31].…”

Section: Introductionmentioning

confidence: 93%

Frailty

Morley

Haren

Rolland

et al. 2006

Medical Clinics of North America

135

View full text Add to dashboard Cite

Frailty is a common condition in older people. It now can be objectively defined by the Fried criteria. When recognized, early intervention should begin with the institution of endurance, resistance, and balance exercises. In men with testosterone deficiency a trial of testosterone replacement should be considered. Vitamin D deficiency needs to be recognized and treated. Appropriate treatment of underlying diseases, such as anemia, diabetes mellitus, and congestive heart failure, are a key management principle. In people who have frailty aggressive health promotion and disease prevention techniques can lead to an inhibition of the downward spiral to disability.

show abstract

Section: Introductionmentioning

confidence: 93%

Frailty

Morley

Haren

Rolland

et al. 2006

Medical Clinics of North America

135

View full text Add to dashboard Cite

show abstract

“…Provided there was this periodic follow-up and a tailored dosage, in the published studies the complications were limited, predictable and manageable, but the follow-up was short and currently safety may not be affirmed after 3 years. Conversely current data does not support T supplementation in asymptomatic men with low normal T level [21].…”

Section: Jacques Buvat and Gilbert Boujadouémentioning

confidence: 86%

Testosterone replacement therapy in the ageing man

BuvatJacques

BoujadouéGilbert

2005

The Journal of Men's Health & Gender

View full text Add to dashboard Cite

“…38 Nevertheless, testosterone deficiency is most often defined as a serum testosterone <300 ng/dL (10.4 nmol/L) 39 and there is a general agreement that total testosterone levels above 346 ng/dL (12 nmol/L) do not require substitution. [40][41] In this review, the average testosterone level for all studies was just below 300 ng/dL (296 ± 85 ng/dL) despite the fact that most studies included low-normal levels of testosterone, up to 400 ng/ dL (13.8 nmol/L). Furthermore, the fact that some hypogonadal men respond fully to PDE-5 inhibitors 28 suggests that their efficacy may depend on minimal levels of circulating testosterone.…”

Section: Discussionmentioning

confidence: 99%

Synergetic effect of testosterone and phophodiesterase-5 inhibitors

Alhathal

Elshal

Carrier

2013

CUAJ

View full text Add to dashboard Cite

Testosterone deficiency seems to impair the clinical response to phophodiesterase-5 (PDE-5) inhibitors in patients with erectile dysfunction (ED). In hypogonadal men, testosterone repletion was associated with enhanced sexual function in patients who failed initial treatment with sildenafil or tadalafil. We conducted a systematic review of studies that evaluated combination therapy of testosterone and PDE-5 inhibitors in patients with ED and low, low-normal testosterone levels who failed monotherapy. The studies we examine are heterogeneous with several methodological drawbacks and that, overall, the addition of testosterone to PDE-5 inhibitors might benefit patients with ED associated with testosterone <300 ng/dL (10.4 nmol/L) who failed monotherapy. Further studies, with a randomized placebo-controlled and double blind design, are needed to describe the appropriate target patient group, testosterone cut-off and to define the optimal dose and duration of combination therapy.

show abstract

Investigation, Treatment and Monitoring of Late-Onset Hypogonadism in Males

Cited by 189 publications

References 0 publications

Frailty

Frailty

Testosterone replacement therapy in the ageing man

Synergetic effect of testosterone and phophodiesterase-5 inhibitors

Contact Info

Product

Resources

About